Moderna (MRNA)

Executive Summary

Moderna, Inc. (NASDAQ: MRNA) leverages its proprietary mRNA platform to develop vaccines and therapeutics, with a rich pipeline targeting infectious diseases, oncology, and rare conditions. Following the commercial success of its COVID-19 vaccine, SPIKEVAX®, the company is advancing next-generation programs, including a respiratory syncytial virus (RSV) vaccine (mRNA-1345) in Phase 3 with topline data expected in 2026, an mRNA-based influenza vaccine (mRNA-1010) in Phase 2, and a combination respiratory vaccine (mRNA-1010) targeting SARS-CoV-2, influenza, and RSV in Phase 1. While Moderna faces declining COVID vaccine sales and intense competition, its innovative pipeline and strong cash position provide a foundation for long-term growth. Key near-term catalysts include Phase 3 data for its RSV vaccine and updates on its flu program, which could validate its platform beyond COVID and drive significant valuation upside.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 RSV Vaccine (mRNA-1345) Data Readout and Potential Approval70% success
• Q4 2026Phase 2 Influenza Vaccine (mRNA-1010) Efficacy Results55% success
• Q2 2026Phase 1 Combination Respiratory Vaccine (mRNA-1010) Initial Data40% success